Davita-Garden Grove Harbor Dialysis is a medicare approved dialysis facility center in Garden Grove, California and it has 24 dialysis stations. It is located in Orange county at 13054 North Harbor Blvd., Garden Grove, CA, 92843. You can reach out to the office of Davita-Garden Grove Harbor Dialysis at (714) 539-3395. This dialysis clinic is managed and/or owned by Davita. Davita-Garden Grove Harbor Dialysis has the following ownership type - Profit. It was first certified by medicare in September, 2015. The medicare id for this facility is 552781 and it accepts patients under medicare ESRD program.
| Name | Davita-Garden Grove Harbor Dialysis |
|---|---|
| Location | 13054 North Harbor Blvd., Garden Grove, California |
| No. of Dialysis Stations | 24 |
| Medicare ID | 552781 |
| Managed By | Davita |
| Ownership Type | Profit |
| Late Shifts | No |
| 13054 North Harbor Blvd., Garden Grove, California, 92843 | |
| (714) 539-3395 | |
News Archive
A team of Weizmann Institute scientists has turned the tables on an autoimmune disease. In such diseases, including Crohn's and rheumatoid arthritis, the immune system mistakenly attacks the body's tissues. But the scientists managed to trick the immune systems of mice into targeting one of the body's players in autoimmune processes, an enzyme known as MMP9.
A new report, published today in PLoS One shows that RADARS(R) System Poison Center data can be used to predict methadone overdose trends in the U.S.
Cadence Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has classified the OFIRMEV™ (acetaminophen) injection New Drug Application (NDA) resubmission as a complete Class 2 response to the FDA's February 10, 2010 action letter and assigned a new Prescription Drug User Fee Act (PDUFA) action date of November 4, 2010.
An Australian-led global initiative to improve the diagnosis of genetic disorders and reduce errors in the reporting of genetic variations has been published today in the prestigious scientific journal Science.
› Verified 9 days ago
| NPI Number | 1619397700 |
| Organization Name | Garden Grove Harbor Dialysis |
| Doing Business As | Edisto Dialysis Llc |
| Address | 13054 Harbor Blvd Garden Grove, California, 92843 |
| Phone Number | (714) 539-3395 |
News Archive
A team of Weizmann Institute scientists has turned the tables on an autoimmune disease. In such diseases, including Crohn's and rheumatoid arthritis, the immune system mistakenly attacks the body's tissues. But the scientists managed to trick the immune systems of mice into targeting one of the body's players in autoimmune processes, an enzyme known as MMP9.
A new report, published today in PLoS One shows that RADARS(R) System Poison Center data can be used to predict methadone overdose trends in the U.S.
Cadence Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has classified the OFIRMEV™ (acetaminophen) injection New Drug Application (NDA) resubmission as a complete Class 2 response to the FDA's February 10, 2010 action letter and assigned a new Prescription Drug User Fee Act (PDUFA) action date of November 4, 2010.
An Australian-led global initiative to improve the diagnosis of genetic disorders and reduce errors in the reporting of genetic variations has been published today in the prestigious scientific journal Science.
› Verified 9 days ago
| Dialysis patients with Hemoglobin data | 37 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 14 |
News Archive
A team of Weizmann Institute scientists has turned the tables on an autoimmune disease. In such diseases, including Crohn's and rheumatoid arthritis, the immune system mistakenly attacks the body's tissues. But the scientists managed to trick the immune systems of mice into targeting one of the body's players in autoimmune processes, an enzyme known as MMP9.
A new report, published today in PLoS One shows that RADARS(R) System Poison Center data can be used to predict methadone overdose trends in the U.S.
Cadence Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has classified the OFIRMEV™ (acetaminophen) injection New Drug Application (NDA) resubmission as a complete Class 2 response to the FDA's February 10, 2010 action letter and assigned a new Prescription Drug User Fee Act (PDUFA) action date of November 4, 2010.
An Australian-led global initiative to improve the diagnosis of genetic disorders and reduce errors in the reporting of genetic variations has been published today in the prestigious scientific journal Science.
› Verified 9 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 100 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 755 |
| Percentage of adult patients getting regular hemodialysis at the center | 93 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
A team of Weizmann Institute scientists has turned the tables on an autoimmune disease. In such diseases, including Crohn's and rheumatoid arthritis, the immune system mistakenly attacks the body's tissues. But the scientists managed to trick the immune systems of mice into targeting one of the body's players in autoimmune processes, an enzyme known as MMP9.
A new report, published today in PLoS One shows that RADARS(R) System Poison Center data can be used to predict methadone overdose trends in the U.S.
Cadence Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has classified the OFIRMEV™ (acetaminophen) injection New Drug Application (NDA) resubmission as a complete Class 2 response to the FDA's February 10, 2010 action letter and assigned a new Prescription Drug User Fee Act (PDUFA) action date of November 4, 2010.
An Australian-led global initiative to improve the diagnosis of genetic disorders and reduce errors in the reporting of genetic variations has been published today in the prestigious scientific journal Science.
› Verified 9 days ago
| Adult patients getting regular peritoneal dialysis at the center | 5 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 34 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
A team of Weizmann Institute scientists has turned the tables on an autoimmune disease. In such diseases, including Crohn's and rheumatoid arthritis, the immune system mistakenly attacks the body's tissues. But the scientists managed to trick the immune systems of mice into targeting one of the body's players in autoimmune processes, an enzyme known as MMP9.
A new report, published today in PLoS One shows that RADARS(R) System Poison Center data can be used to predict methadone overdose trends in the U.S.
Cadence Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has classified the OFIRMEV™ (acetaminophen) injection New Drug Application (NDA) resubmission as a complete Class 2 response to the FDA's February 10, 2010 action letter and assigned a new Prescription Drug User Fee Act (PDUFA) action date of November 4, 2010.
An Australian-led global initiative to improve the diagnosis of genetic disorders and reduce errors in the reporting of genetic variations has been published today in the prestigious scientific journal Science.
› Verified 9 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Davita-Garden Grove Harbor Dialysis with elevated calcium levels.
| Patients with hypercalcemia | 112 |
| Hypercalcemia patient months | 865 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 1 |
| Patients with Serumphosphor | 123 |
| Patients with Serumphosphor less than 3.5 mg/dL | 11 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 28 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 35 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 14 |
| Patients with Serumphosphor greater than 7 mg/dL | 11 |
News Archive
A team of Weizmann Institute scientists has turned the tables on an autoimmune disease. In such diseases, including Crohn's and rheumatoid arthritis, the immune system mistakenly attacks the body's tissues. But the scientists managed to trick the immune systems of mice into targeting one of the body's players in autoimmune processes, an enzyme known as MMP9.
A new report, published today in PLoS One shows that RADARS(R) System Poison Center data can be used to predict methadone overdose trends in the U.S.
Cadence Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has classified the OFIRMEV™ (acetaminophen) injection New Drug Application (NDA) resubmission as a complete Class 2 response to the FDA's February 10, 2010 action letter and assigned a new Prescription Drug User Fee Act (PDUFA) action date of November 4, 2010.
An Australian-led global initiative to improve the diagnosis of genetic disorders and reduce errors in the reporting of genetic variations has been published today in the prestigious scientific journal Science.
› Verified 9 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 85 |
| Patient months included in arterial venous fistula and catheter summaries | 498 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 71 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 16 |
News Archive
A team of Weizmann Institute scientists has turned the tables on an autoimmune disease. In such diseases, including Crohn's and rheumatoid arthritis, the immune system mistakenly attacks the body's tissues. But the scientists managed to trick the immune systems of mice into targeting one of the body's players in autoimmune processes, an enzyme known as MMP9.
A new report, published today in PLoS One shows that RADARS(R) System Poison Center data can be used to predict methadone overdose trends in the U.S.
Cadence Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has classified the OFIRMEV™ (acetaminophen) injection New Drug Application (NDA) resubmission as a complete Class 2 response to the FDA's February 10, 2010 action letter and assigned a new Prescription Drug User Fee Act (PDUFA) action date of November 4, 2010.
An Australian-led global initiative to improve the diagnosis of genetic disorders and reduce errors in the reporting of genetic variations has been published today in the prestigious scientific journal Science.
› Verified 9 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 55 |
| Hospitalization Rate in facility | 184.5 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 340.6 |
| Hospitalization Rate: Lower Confidence Limit | 104.4 |
News Archive
A team of Weizmann Institute scientists has turned the tables on an autoimmune disease. In such diseases, including Crohn's and rheumatoid arthritis, the immune system mistakenly attacks the body's tissues. But the scientists managed to trick the immune systems of mice into targeting one of the body's players in autoimmune processes, an enzyme known as MMP9.
A new report, published today in PLoS One shows that RADARS(R) System Poison Center data can be used to predict methadone overdose trends in the U.S.
Cadence Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has classified the OFIRMEV™ (acetaminophen) injection New Drug Application (NDA) resubmission as a complete Class 2 response to the FDA's February 10, 2010 action letter and assigned a new Prescription Drug User Fee Act (PDUFA) action date of November 4, 2010.
An Australian-led global initiative to improve the diagnosis of genetic disorders and reduce errors in the reporting of genetic variations has been published today in the prestigious scientific journal Science.
› Verified 9 days ago
The rate of readmission show you whether patients who were being treated regularly at Davita-Garden Grove Harbor Dialysis were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 18.2 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 27.8 |
| Readmission Rate: Lower Confidence Limit | 10.7 |
News Archive
A team of Weizmann Institute scientists has turned the tables on an autoimmune disease. In such diseases, including Crohn's and rheumatoid arthritis, the immune system mistakenly attacks the body's tissues. But the scientists managed to trick the immune systems of mice into targeting one of the body's players in autoimmune processes, an enzyme known as MMP9.
A new report, published today in PLoS One shows that RADARS(R) System Poison Center data can be used to predict methadone overdose trends in the U.S.
Cadence Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has classified the OFIRMEV™ (acetaminophen) injection New Drug Application (NDA) resubmission as a complete Class 2 response to the FDA's February 10, 2010 action letter and assigned a new Prescription Drug User Fee Act (PDUFA) action date of November 4, 2010.
An Australian-led global initiative to improve the diagnosis of genetic disorders and reduce errors in the reporting of genetic variations has been published today in the prestigious scientific journal Science.
› Verified 9 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Davita-Garden Grove Harbor Dialysis get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | 1.24 (As Expected) |
| SIR: Upper Confidence Limit | 2.57 |
| SIR: Lower Confidence Limit | .5 |
News Archive
A team of Weizmann Institute scientists has turned the tables on an autoimmune disease. In such diseases, including Crohn's and rheumatoid arthritis, the immune system mistakenly attacks the body's tissues. But the scientists managed to trick the immune systems of mice into targeting one of the body's players in autoimmune processes, an enzyme known as MMP9.
A new report, published today in PLoS One shows that RADARS(R) System Poison Center data can be used to predict methadone overdose trends in the U.S.
Cadence Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has classified the OFIRMEV™ (acetaminophen) injection New Drug Application (NDA) resubmission as a complete Class 2 response to the FDA's February 10, 2010 action letter and assigned a new Prescription Drug User Fee Act (PDUFA) action date of November 4, 2010.
An Australian-led global initiative to improve the diagnosis of genetic disorders and reduce errors in the reporting of genetic variations has been published today in the prestigious scientific journal Science.
› Verified 9 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Davita-Garden Grove Harbor Dialysis's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 45 |
| Transfusion Rate in facility | 37.5 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 121.7 |
| Transfusion Rate: Lower Confidence Limit | 13.3 |
News Archive
A team of Weizmann Institute scientists has turned the tables on an autoimmune disease. In such diseases, including Crohn's and rheumatoid arthritis, the immune system mistakenly attacks the body's tissues. But the scientists managed to trick the immune systems of mice into targeting one of the body's players in autoimmune processes, an enzyme known as MMP9.
A new report, published today in PLoS One shows that RADARS(R) System Poison Center data can be used to predict methadone overdose trends in the U.S.
Cadence Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has classified the OFIRMEV™ (acetaminophen) injection New Drug Application (NDA) resubmission as a complete Class 2 response to the FDA's February 10, 2010 action letter and assigned a new Prescription Drug User Fee Act (PDUFA) action date of November 4, 2010.
An Australian-led global initiative to improve the diagnosis of genetic disorders and reduce errors in the reporting of genetic variations has been published today in the prestigious scientific journal Science.
› Verified 9 days ago
The rate of mortality show you whether patients who were being treated regularly at Davita-Garden Grove Harbor Dialysis lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 89 |
| Mortality Rate in facility | 19.9 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 39.2 |
| Mortality Rate: Lower Confidence Limit | 8.6 |
News Archive
A team of Weizmann Institute scientists has turned the tables on an autoimmune disease. In such diseases, including Crohn's and rheumatoid arthritis, the immune system mistakenly attacks the body's tissues. But the scientists managed to trick the immune systems of mice into targeting one of the body's players in autoimmune processes, an enzyme known as MMP9.
A new report, published today in PLoS One shows that RADARS(R) System Poison Center data can be used to predict methadone overdose trends in the U.S.
Cadence Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has classified the OFIRMEV™ (acetaminophen) injection New Drug Application (NDA) resubmission as a complete Class 2 response to the FDA's February 10, 2010 action letter and assigned a new Prescription Drug User Fee Act (PDUFA) action date of November 4, 2010.
An Australian-led global initiative to improve the diagnosis of genetic disorders and reduce errors in the reporting of genetic variations has been published today in the prestigious scientific journal Science.
› Verified 9 days ago
Fmc-Rai-Garden Grove Blvd.-Garden Grove Location: 12555 Garden Grove Blvd., Suite 100, Garden Grove, California, 92843 Phone: (714) 741-7255 |
Fmc-Rai-Harbor Blvd.-Garden Grove Location: 12761 Harbor Blvd., Suite I-3, Garden Grove, California, 92840 Phone: (714) 539-3122 |
Davita-Garden Grove Harbor Dialysis Location: 13054 North Harbor Blvd., Garden Grove, California, 92843 Phone: (714) 539-3395 |
News Archive
A team of Weizmann Institute scientists has turned the tables on an autoimmune disease. In such diseases, including Crohn's and rheumatoid arthritis, the immune system mistakenly attacks the body's tissues. But the scientists managed to trick the immune systems of mice into targeting one of the body's players in autoimmune processes, an enzyme known as MMP9.
A new report, published today in PLoS One shows that RADARS(R) System Poison Center data can be used to predict methadone overdose trends in the U.S.
Cadence Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has classified the OFIRMEV™ (acetaminophen) injection New Drug Application (NDA) resubmission as a complete Class 2 response to the FDA's February 10, 2010 action letter and assigned a new Prescription Drug User Fee Act (PDUFA) action date of November 4, 2010.
An Australian-led global initiative to improve the diagnosis of genetic disorders and reduce errors in the reporting of genetic variations has been published today in the prestigious scientific journal Science.
› Verified 9 days ago